After price correction, more than 300 drug regulations in the province were withdrawn from the Internet

From the "4+7" centralized drug procurement at the end of 2018 to now, the National Medical Insurance Bureau has organized and completed 6 batches of drug procurement, covering 234 varieties
.
In this context, the water price of medicines is being squeezed out continuously
.
It is worth noting that, in addition to the drugs that are included in the centralized procurement, many provinces have begun to develop new "bargaining plans" for those varieties that are not included in the centralized procurement
.
For example, recently, the Hunan Provincial Public Resource Trading Center announced the "Declaration Results of Some Drug Price Correction and Price Restricted Internet-listed Enterprises", including 10 generic names for the gastrointestinal drug Famotidine and the cardiovascular and cerebrovascular drug Ligustrazine.
Involves 340 product gauges
.
Among them, only 17 products are still listed after price reduction, and the other 323 varieties are all withdrawn
.
It is understood that these 10 varieties are relatively competitive fields
.
Due to many mutual complaints, real-name reports of inflated prices, etc.
, they were rectified
.
It is worth mentioning that industry analysts believe that the price correction in Hunan this time involves all varieties other than the national centralized procurement.
Therefore, Hunan's "price correction" is undoubtedly another powerful effect on the national centralized procurement price control effect.
supplement
.
In fact, under the general trend of national centralized drug procurement in recent years, for a large number of pharmaceutical companies and drugs that were not selected, they have been subject to more and more strict supervision due to the influence of the national drug price linkage mechanism
.
At present, in addition to Hunan Province, many provinces and cities have issued relevant documents
.
For example, the Jilin Provincial Government Procurement Center has earlier issued the "Notice on Announcement of the Dynamic Linkage Results of "Six Provinces and Two Districts" Centralized Procurement of Non-selected Drugs and "On the Announcement of the Fourth Batch of National Organizations and "Six Provinces and Two Districts" Selected Announcement on the National Provincial Lowest Winning Bid (On-line) Price for Drugs with the Same or Similar Chemical Active Ingredients
.
In 2020, Liaoning Province also requires that the unselected drugs included in the scope of centralized drug procurement organized by the state implement a linked gradient price reduction
.
It also implemented a gradient price reduction for 55 varieties of anastrozole oral normal-release dosage forms, involving 662 product specifications and 315 drugs from 315 companies.
Through the independent declaration of enterprises, a total of 148 product specifications that met the requirements for gradient price reduction, with an average reduction of 21.
1 %
.
In addition, many provinces have adopted price linkage testing for online varieties.
For example, Liaoning and other provinces have announced information on active price reductions for tens of thousands of varieties.
" evaluation
.
In this context, the industry believes that for some pharmaceutical companies, under the national drug price linkage mechanism, the emergence of new product regulations in each city's procurement with volume may become the driving force behind the nationwide price decline of the company's drugs
.
In the future, more and more pharmaceutical companies will face pressures from both volume and price
.
For pharmaceutical companies, in order to develop better, they must accelerate transformation, change the pharmaceutical marketing model, and increase investment in innovation
.
It is reported that a large number of companies such as Hengrui, CSPC, Kelun, etc.
have already transformed to innovative drugs and generic drugs; and Watson Pharmaceuticals, Nhua Pharmaceuticals, etc.
have also begun to adjust their sales departments
.